Based on these results, daratumumab is being evaluated in a phase 2 clinical trial in patients with CD38‐positive mantle cell lymphoma, diffuse large B‐cell lymphoma, or follicular lymphoma (Table 1). This evidence concerns the gene CD38 and diffuse large B-cell lymphoma.